Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma

Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma

Abstract Background The efficacy and safety of bevacizumab-containing chemotherapy for patients with metastatic duodenal and jejunal adenocarcinoma (mDJA) are unclear. The present study aimed to evaluate the efficacy of bevacizumab and to explore immunohistochemical markers that can predict the effi...

Full description

Bibliographic Details
Main Authors: Takahiro Amano, Hideki Iijima, Shinichiro Shinzaki, Taku Tashiro, Shuko Iwatani, Mizuki Tani, Yuriko Otake, Takeo Yoshihara, Aya Sugimoto, Satoshi Egawa, Shinjiro Yamaguchi, Kazuo Kinoshita, Manabu Araki, Motohiro Hirao, Yuko Sakakibara, Satoshi Hiyama, Hiroyuki Ogawa, Koji Nagaike, Jun Murata, Masato Komori, Yorihide Okuda, Takashi Kizu, Yoshiki Tsujii, Yoshito Hayashi, Takahiro Inoue, Hidekazu Takahashi, Tsunekazu Mizushima, Eiichi Morii, Tetsuo Takehara
Format: Article
Language:English
Published: BMC 2021-08-01
Series:BMC Cancer
Subjects:
Small bowel adenocarcinoma
Duodenal and jejunal adenocarcinoma
VEGF-A
Immunohistochemical expressions
Bevacizumab
Online Access:https://doi.org/10.1186/s12885-021-08724-5

Internet

https://doi.org/10.1186/s12885-021-08724-5

Similar Items